Eli Lilly (LLY) Stock Trades At A Discount After Its 439% Run

Eli Lilly has turned into one of the most closely watched pharmaceutical stocks, with the share price at US$1,183.46 and a very large 5 year gain putting fresh focus on whether the underlying cash flows can carry that kind of valuation. After such a strong stretch, the key issue for you is whether the stock price still matches what the company’s future cash generation can support.

• The stock has returned 439.4% over 5 years, which puts a lot of weight on the question of how much cash Eli Lilly can realistically produce and sustain over time.
• Recent FDA approvals, new drug launches and large scale manufacturing investments may support expectations for higher revenue and cash inflows, but they can also reshape the timing and size of future outlays and risks that need to be built into any valuation work.
• If you'd rather focus on earnings, this one's for you. See what Eli Lilly's 39.5x P/E says about the price.

The issue now is whether today’s price is adequately backed by the cash flows that Eli Lilly is expected to generate over the coming years under a Discounted Cash Flow (DCF) view.

If Eli Lilly's run has you thinking more carefully about what you are paying for future cash flows, a focused stock screen built around similar quality filters can be a useful second reference point through 32 high quality undervalued stocks

Is Eli Lilly Still Cheap on Cash Flow?

The Discounted Cash Flow (DCF) model here is built on the cash the business can return to shareholders over time. Eli Lilly generated about $13.6b in free cash flow over the last twelve months, and the model assumes those cash flows keep growing from that base rather than flattening out or shrinking. That growth path is reflected in rising projected free cash flows over the next decade, then a slower second stage as the company matures.

On those assumptions, the DCF output suggests Eli Lilly’s intrinsic value sits substantially above the current share price of $1,183.46. The recent FDA approval of Onswik for once weekly insulin use helps explain why analysts are comfortable modelling higher future cash generation, even if the market price has already moved a long way. If you want to see how that gap is quantified, along with the detailed cash flow path and discount rate inputs, you can explore the full model through. Find out what Eli Lilly could be worth using our Discounted Cash Flow (DCF) estimate.

The Eli Lilly Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Eli Lilly pick up where the DCF puzzle leaves off and spell out which assumptions on growth, margins and earnings would need to hold for the stock to be worth materially more or less than the current share price, all housed on the Community page. Each storyline ties a fair value estimate to a clear set of potential catalysts and risks so you can track over time which version of Eli Lilly's future seems to be unfolding in real life.

Community views on Eli Lilly are split between one camp that sees the current price as roughly fair value and another that thinks expectations run ahead of themselves.

Bull case: roughly fairly valued

"Market penetration for all GLP-1 drugs is only at 4% of a target audience of 100 to 120 million people in the USA alone…"

Discover why this Narrative puts Eli Lilly at roughly fairly valued.

Bear case: 21% overvalued

"Heavily concentrated revenue in a narrow set of leading drugs, including Mounjaro, Zepbound, and Trulicity, makes Lilly especially vulnerable…"

Explore why this Narrative puts Eli Lilly at 21% overvalued.

One more Eli Lilly angle worth checking before you decide what the price means

Eli Lilly’s valuation story is only half the picture, because the internal checks on this business have also flagged specific concerns that could matter a lot to your thesis. Take a closer look at 1 warning sign before settling on a valuation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com